Related Experiment Video
Updated: Apr 21, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins: Can we advocate them for primary prevention of heart disease?
Sougat Ray1, A K Jindal2, S Sengupta3
1Associate Professor, Dept of Community Medicine, Armed Forces Medical College, Pune 411040, India.
Insights
Statins, or HMG-CoA reductase inhibitors, significantly reduce cardiovascular events in both secondary and primary prevention. While effective, ongoing debate addresses their cost-effectiveness and potential adverse effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- Cholesterol-lowering agents, specifically statins (HMG-CoA reductase inhibitors), have been central to numerous clinical trials.
- Early trials like the Scandinavian Simvastatin Survival Study (4S) demonstrated significant reductions in coronary events and mortality.
- The focus has expanded from secondary to primary prevention, evaluating statins in apparently healthy individuals.
Purpose of the Study:
- To review the established benefits of statins in cholesterol reduction and cardiovascular event prevention.
- To discuss the evolving role of statins in primary prevention strategies.
- To explore potential pleiotropic effects and ongoing concerns regarding statin therapy.
Main Methods:
- Review of landmark cholesterol reduction trials, including the Scandinavian Simvastatin Survival Study (4S).
- Analysis of evidence from primary prevention trials such as JUPITER and Cholesterol Treatment Trialists (CTT) collaborators.
- Discussion of reported pleiotropic effects and adverse events associated with statin use.
Main Results:
- Statins demonstrated a 44% reduction in major coronary events and a 30% reduction in total mortality in hypercholesterolemic men with CHD (4S trial).
- Primary prevention trials confirmed that statins reduce first major cardiovascular events in apparently healthy individuals.
- Statins are associated with potential benefits in other conditions and known adverse effects like myositis and transaminitis.
Conclusions:
- Statins are proven effective in reducing cardiovascular events for both secondary and primary prevention.
- The debate continues regarding the cost-effectiveness and management of adverse effects of statins.
- Further consensus is needed within the medical community on the optimal use of statins.
Abstract:
The discovery of cholesterol-lowering agents, namely HMG-CoA reductase inhibitors or statins, ushered in a series of large cholesterol reduction trials. The first of these studies was the Scandinavian Simvastatin Survival Study (4S) in which hypercholesterolemic men with CHD who were treated with simvastatin had a reduction in major coronary events of 44% and a reduction in total mortality of 30%. Many more secondary prevention trials followed to establish unequivocally the benefit of cholesterol reduction. Strategies that aim to improve primary prevention are important for managing the overall burden of disease. Recently therefore, the role of statin in primary prevention is being debated. The JUPITER trial and more recently the Cholesterol Treatment Trialists collaborators, proved that incidences of first major cardiovascular events in apparently healthy individuals were reduced by statins. Statins have also been discussed to be having certain pleiotropic effects on other diseases like diabetes, cancer and osteoporosis. However, issues of cost effectiveness and adverse effects like myositis, and transaminitis still loom large. The medical community needs to debate and evolve a possible consensus on the path breaking subject.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:26Angina IV: Management